Lacidipine Doc Generici

Lacidipine, the active ingredient in Lacidipine Doc Generici, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering blood pressure. The medication works by relaxing vascular smooth muscle, leading to vasodilation and reduced systemic vascular resistance.

GNH USA supplies Lacidipine Doc Generici as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory‑compliant packaging for export. All shipments are tracked and insured.

Lacidipine is a dihydropyridine calcium channel blocker used to manage high blood pressure and related cardiovascular conditions.

- Hypertension: lowers both systolic and diastolic blood pressure, helping to achieve target levels in patients with primary hypertension. - Essential hypertension: provides sustained blood pressure control as part of combination therapy for patients requiring long‑term management. - Isolated systolic hypertension: effectively reduces elevated systolic pressure in older adults where diastolic values remain normal.

Lacidipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Tachycardia: increased heart rate without accompanying symptoms. - Nausea: mild stomach discomfort or urge to vomit.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause fainting. - Angioedema: swelling of the face, lips, tongue, or throat requiring immediate medical attention. - Myocardial infarction: rare occurrence of heart attack symptoms. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, itching, or anaphylaxis. - Neutropenia: significant reduction in white blood cells.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use caution and consider dose adjustment in patients with liver disease. - Concomitant antihypertensives: evaluate for additive blood‑pressure‑lowering effects. - Heart failure: monitor for signs of fluid overload or worsening symptoms. - Abrupt discontinuation: avoid sudden stop to prevent rebound hypertension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Nitrates: combined use may cause profound hypotension. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lacidipine plasma levels, raising risk of adverse effects. - Grapefruit juice: can markedly elevate drug concentrations.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (beta‑blockers, ACE inhibitors, diuretics): may enhance blood‑pressure‑lowering effect. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lacidipine effectiveness. - Antidiabetic agents: monitor glucose control as blood‑pressure changes can affect glycemic levels.